You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,205,045

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,205,045

Title:	Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
Abstract:	Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	14/812,989
Patent Claims:	1. A method of treating pain comprising administering denosumab to relieve osteoarthritis pain in a mammal in need thereof, wherein the mammal has a bone marrow lesion. 2. The method of claim 1, wherein the denosumab is administered subcutaneously. 3. The method of claim 2, wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a four week period. 4. The method of claim 3, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a four week period. 5. The method of claim 2, wherein about 30 mg to about 180 mg of denosumab is administered to the mammal no more than once a week. 6. The method of claim 5, wherein about 30 mg to about 180 mg of denosumab is administered weekly to the mammal for two to four weeks. 7. The method of claim 2, wherein about 100 mg to about 140 mg of denosumab is administered to the mammal over a three to five week period. 8. The method of claim 2, wherein about 120 mg of denosumab is administered to the mammal over a four week period. 9. The method of claim 1, wherein the denosumab is administered intravenously. 10. The method of claim 1, wherein the denosumab is administered intramuscularly. 11. The method of claim 1, wherein the denosumab is administered intradermally. 12. The method of claim 1, wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a four week period. 13. The method of claim 1, wherein about 1 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a three to five week period. 14. The method of claim 1, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a three to five week period. 15. The method of claim 1, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a four week period. 16. The method of claim 1, wherein about 120 mg of denosumab is administered to the mammal over a four week period. 17. The method of claim 1, wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the mammal. 18. The method of claim 1, wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the mammal. 19. The method of claim 1, wherein the mammal is a human being. 20. The method of claim 1, wherein the osteoarthritis affects a knee or hip. 21. The method of claim 1, wherein the osteoarthritis affects an elbow, a shoulder, a wrist, or a finger.

Details for Patent 9,205,045

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010	⤷ Try a Trial	2034-06-11
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010	⤷ Try a Trial	2034-06-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.